This is the latest episode of the free DDW podcast, “The next steps in the fight against cancer”. It covers two articles written for Volume 22, Issue 4 – Fall 2021 of DDW. They are called “Accelerating research: the path forward for treating rare cancers” and “Inside combination immunotherapies for cancer”.
RareCan is a new company based in the UK. Its aim is to accelerate research into rare cancers. However, finding suitable patients willing to take part in research and trials of new drugs is difficult, which impacts the discovery process. In the first article, Professor Andy Hall, Founding Director and Chief Scientific Officer at RareCan talks to DDW’s Megan Thomas.
Combination immunotherapies are one of the most exciting advanced therapy medicinal products (ATMP) being developed, with incredible potential for treating cancer, says Panagiotis Parsonidis, a molecular biologist and lead researcher at RGCC. DDW speaks to him about VAXO-Q-RE developments, a combination immunotherapy that will soon enter clinical trials.
You can also find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.